Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

873 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Population pharmacokinetics and exposure-response assessment of veliparib co-administered with temozolomide in patients with myeloid leukemias.
Singh R, Mehrotra S, Gopalakrishnan M, Gojo I, Karp JE, Greer JM, Chen A, Piekarz R, Kiesel BF, Gobburu J, Rudek MA, Beumer JH; ETCTN-6745 study team. Singh R, et al. Among authors: mehrotra s. Cancer Chemother Pharmacol. 2019 Feb;83(2):319-328. doi: 10.1007/s00280-018-3731-4. Epub 2018 Nov 20. Cancer Chemother Pharmacol. 2019. PMID: 30456480 Free PMC article. Clinical Trial.
Personalized Management of Chemotherapy-Induced Peripheral Neuropathy Based on a Patient Reported Outcome: CALGB 40502 (Alliance).
Sharma MR, Mehrotra S, Gray E, Wu K, Barry WT, Hudis C, Winer EP, Lyss AP, Toppmeyer DL, Moreno-Aspitia A, Lad TE, Velasco M, Overmoyer B, Rugo HS, Ratain MJ, Gobburu JV. Sharma MR, et al. Among authors: mehrotra s. J Clin Pharmacol. 2020 Apr;60(4):444-452. doi: 10.1002/jcph.1559. Epub 2019 Dec 4. J Clin Pharmacol. 2020. PMID: 31802506 Free PMC article.
Parent-Metabolite Pharmacokinetic Modeling and Pharmacodynamics of Veliparib (ABT-888), a PARP Inhibitor, in Patients With BRCA 1/2-Mutated Cancer or PARP-Sensitive Tumor Types.
Niu J, Scheuerell C, Mehrotra S, Karan S, Puhalla S, Kiesel BF, Ji J, Chu E, Gopalakrishnan M, Ivaturi V, Gobburu J, Beumer JH. Niu J, et al. Among authors: mehrotra s. J Clin Pharmacol. 2017 Aug;57(8):977-987. doi: 10.1002/jcph.892. Epub 2017 Apr 7. J Clin Pharmacol. 2017. PMID: 28387939 Free PMC article. Clinical Trial.
Harnessing formulation and clinical pharmacology knowledge for efficient pediatric drug development: Overview and discussions from M-CERSI pediatric formulation workshop 2019.
Khong YM, Liu J, Cook J, Purohit V, Thompson K, Mehrotra S, Cheung SYA, Hay JL, Fletcher EP, Wang J, Sachs HC, Zhu H, Siddiqui A, Cunningham L, Selen A. Khong YM, et al. Among authors: mehrotra s. Eur J Pharm Biopharm. 2021 Jul;164:66-74. doi: 10.1016/j.ejpb.2021.04.010. Epub 2021 Apr 18. Eur J Pharm Biopharm. 2021. PMID: 33878434
Pediatric formulation development - Challenges of today and strategies for tomorrow: Summary report from M-CERSI workshop 2019.
Tan DCT, Khong YM, Mount S, Galella E, Mitra B, Charlton S, Kuhli M, Ternik R, Walsh J, Rajapakshe A, Thompson K, Mehrotra S, Santangelo M, Liu J, Dixit T, Schaufelberger D, Jamzad S, Klein S, Hoag SW, Wang J, Fletcher EP, Khurana M, Alexander J, Radden E, Sood R, Selen A. Tan DCT, et al. Among authors: mehrotra s. Eur J Pharm Biopharm. 2021 Jul;164:54-65. doi: 10.1016/j.ejpb.2021.04.011. Epub 2021 Apr 18. Eur J Pharm Biopharm. 2021. PMID: 33878432
873 results